share_log

Lexicon Pharmaceuticals to Participate in December Investor Conferences

Lexicon Pharmaceuticals to Participate in December Investor Conferences

莱斯康制药将在十二月参加投资者会议
GlobeNewswire ·  2024/11/25 16:15

THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer and director, will present at two upcoming investor conferences in December.

得克萨斯州伍德兰,2024年11月25日(环球新闻通讯社) - 莱斯康制药公司(纳斯达克股票代码:LXRX)今天宣布公司管理层,包括董事长兼首席执行官迈克·埃克斯顿,将于12月参加两场即将举行的投资者会议。

  • Piper Sandler 36th Annual Healthcare Conference: Presentation Tuesday, December 3, 2024 at 8:00 am ET
  • 7th Annual Evercore HealthCONx Conference: Presentation Thursday, December 5, 2024 at 12:30 pm ET
  • 第36届派杰投资健康年会:2024年12月3日星期二,上午8:00(东部时间)报告会
  • 第7届evercore HealthCONx年会:2024年12月5日星期四,下午12:30(东部时间)报告会

Simultaneous webcasts will be available in the "Events" section of the Lexicon website at , and a recording of the webcasts will be available for two weeks following the original on-demand date.

同时网站将在莱斯康网站的“活动”部分提供网络直播,并可回看两周。

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000 program, Lexicon's unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit .

关于莱斯康制药
莱斯康是一家生物制药公司,使命是开发可以改变患者生活的药物。通过Genome5000计划,莱斯康独特的基因组靶点发现平台,莱斯康科学家研究了近5000个基因的作用和功能,并确定了超过100个蛋白靶点,在一系列疾病中具有显著的治疗潜力。通过精确瞄准这些蛋白质,莱斯康正在开拓创新药物的发现和研发,以安全有效地治疗疾病。莱斯康在神经病性疼痛、肥厚型心肌病(HCM)、肥胖、代谢和其他适应症的发现、临床和临床前开发中拥有一系列有前途的候选药物。有关更多信息,请访问。

Investors and Media
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

投资者和媒体
Lisa DeFrancesco
莱斯康制药公司
lexinvest@lexpharma.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发